Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
Conceptus: Birth control device developer's plans for a secondary offering of 4 mil. shares of common stock are outlined in a recent filing with the Securities and Exchange Commission. The filing precedes a scheduled July 22-23 FDA Obstetrics & Gynecology Devices Panel meeting to review data on 400 patients treated with the Essure non-incisional, permanent birth control system, which has been granted fast-track status (1"The Gray Sheet" May 27, 2002, In Brief). The implant is expected to debut in the U.S. next year as an alternative to surgical tubal ligation and vasectomy, which currently account for about 1 mil. procedures annually. All of the shares will be offered by the company with UBS Warburg acting as the sole book-running manager. CIBC World Markets, Adams Harkness & Hill and SG Cowen are acting as co-managers...